Theravance Biopharma
TBPH
TBPH
131 hedge funds and large institutions have $401M invested in Theravance Biopharma in 2025 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 36 increasing their positions, 48 reducing their positions, and 18 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more funds holding in top 10
Funds holding in top 10: →
less ownership
Funds ownership: →
5% less capital invested
Capital invested by funds: $422M → $401M (-$21.5M)
25% less repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 48
63% less call options, than puts
Call options by funds: $6K | Put options by funds: $16K
Holders
131
Holding in Top 10
3
Calls
$6K
Puts
$16K
Top Buyers
| 1 | +$2.17M | |
| 2 | +$1.98M | |
| 3 | +$1.55M | |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$1.11M |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$1.02M |
Top Sellers
| 1 | -$2.47M | |
| 2 | -$2.33M | |
| 3 | -$1.41M | |
| 4 |
State Street
Boston,
Massachusetts
|
-$1.39M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
-$1.08M |